Analysts' Actions -- Chemours, Incyte, Visteon, Toyota and More

RATINGS CHANGES

Chemours (CC) was upgraded to overweight and assigned a $50 price target at JPMorgan. 

GW Pharmaceuticals (GWPH) was downgraded to sell at TheStreet Ratings. You can view the full analysis from the report here: GWPH.

Incyte (INCY) was initiated with a market perform rating and assigned a $125 price target at Oppenheimer. 

Paycom Software (PAYC) was initiated with an outperform rating and $75 price target at Wells Fargo. 

Toyota Motor TM was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: TM.

Ultimate Software (ULTI) was initiated with an outperform rating and $240 price target at Wells Fargo. 

Uni-Pixel (UNXL) was downgraded to neutral and assigned a $0.45 price target at Roth Capital. 

Visteon (VC) was upgraded to overweight at Morgan Stanley and assigned a $115 price target. 

Westlake (WLK) was upgraded to buy and assigned a $71 price target at Tudor Pickering. 

This article was written by a staff member of TheStreet.

More from Stocks

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Will Tesla Stock Tumble 33% to $195?

Will Tesla Stock Tumble 33% to $195?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump